Prev Med Rep

ObjectiveLittle is known about the information providers share with patients when ordering a co-test, or combined human papillomavirus (HPV) and Papanicolaou (Pap) test, for cervical cancer screening. We assessed provider perceptions of such communication practices with female patients aged 30\ue2\u20ac\u201c60 years.MethodsWe analyzed data from 98 providers in 15 Federally Qualified Health Center clinics across Illinois (2009\ue2\u20ac\u201c2010).ResultsAbout 70% of the providers reported that when ordering a co-test, they would usually or always communicate information about the HPV test to their patients, explain the test detects a sexually transmitted infection, and discuss how the test results may determine their next screening interval. Most (>85%) reported that they were comfortable discussing co-test results. Compared with concordant positive results (HPV positive/Pap positive), providers were more likely to perceive that discordant results (HPV positive/Pap negative) would be too complex for patients to understand (25% vs. 15%, p = 0.006), and make patients feel less assured that they were getting the best standard of care (67% vs. 88%, p < 0.001).ConclusionAs HPV testing plays a more prominent role in cervical cancer screening, more attention should be given to communications between providers and patients about the benefits and harms of different screening options.CC999999/Intramural CDC HHS/United States2016-01-01T00:00:00Z26213683PMC451172